Status:
COMPLETED
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Lead Sponsor:
Novartis
Conditions:
Constipation
Eligibility:
FEMALE
18-64 years
Phase:
PHASE4
Brief Summary
To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
Eligibility Criteria
Inclusion
- Females aged 18 to 64 years of age
- Patients with constipation as defined by the Rome II criteria
Exclusion
- Patients who have been previously been treated with tegaserod and/or PEG 3350
- Evidence of cathartic colon or a history of laxative abuse or laxative dependence
- History of fecal impaction which necessitated surgical intervention
- Patients with clinically significant abnormal TSH levels at screening
- Women who are pregnant or breast feeding
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00171522
Start Date
May 1 2005
End Date
September 1 2005
Last Update
March 3 2016
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Harmony Clinical Research
Oro Valley, Arizona, United States, 85739
2
Central Phoenix Medical Clinic, LLC
Phoenix, Arizona, United States, 85201
3
Adobe Gastroenterology, PC
Tucson, Arizona, United States, 85712
4
Associated Pharmaceutical Research Center, Inc
Buena Park, California, United States, 90620